

## POLICY & PRACTICE

### Feds Launch Sickle Cell Campaign

The National Institute of Diabetes and Digestive and Kidney Diseases is spearheading a campaign to stress the importance of careful hemoglobin A<sub>1c</sub> testing in people with diabetes who have sickle cell trait or similar blood disorders. "If you see a significant discrepancy between a patient's A<sub>1c</sub> reading and the results of routine blood glucose monitoring, consider the possibility that your patient may have a hemoglobin variant and find out if your lab is using an accurate method to measure A<sub>1c</sub>," Dr. Griffin P. Rodgers, NDDK director, said in a statement. In diabetes patients of African, Mediterranean, or Southeast Asian descent, several situations may raise suspicions of a hemoglobin variant, such as an HbA<sub>1c</sub> test result that does not correlate with results of self-blood glucose monitoring, a result that radically differs from a previous test result after a change in lab methods, or a result higher than 15%. "In the United States, more than 3,000 labs rely on 20 different methods to measure A<sub>1c</sub> in people with diabetes," Randie Little, Ph.D., who heads the National Glycohemoglobin Standardization Program, said in a statement. "However, six of these methods yield unreliable results in patients with sickle cell trait." More information for physicians and patients can be found at [www.diabetes.niddk.nih.gov](http://www.diabetes.niddk.nih.gov).

### Part D Plans Not Tracking Costs

Medicare drug plans have not met all requirements for tracking out-of-pocket spending by beneficiaries in the Medicare Part D prescription drug program, accord-

ing to a report from the Health and Human Services Department Office of Inspector General. Tracking out-of-pocket costs is needed to determine when each beneficiary has reached the required spending threshold at which Medicare's catastrophic drug coverage starts. "Implementing the program has been a large undertaking for [the Centers for Medicare and Medicaid Services], its contractors, and the private Part D plans," said HHS Inspector General Daniel Levinson in a statement. "[Medicare] should place more emphasis on conducting Part D oversight." The report found that 29% of Part D plans did not submit required information to the Centers for Medicare and Medicaid Services (CMS) on enrollees' additional drug coverage data. And 34% of Part D plans—covering nearly half of Part D enrollees—did not submit prescription drug event data to CMS in the required time frames. In addition, the limited oversight CMS has conducted so far on Part D plans' tracking of out-of-pocket costs relied on plans' self-reported data. And even then, about half of the plans were not in compliance with one or more of four CMS requirements in this area. The full report is available at [www.oig.hhs.gov](http://www.oig.hhs.gov).

### FDA Can't Fulfill Mission

Three members of the Food and Drug Administration's Science Board issued a damning report on the state of the agency, saying that "the agency suffers from serious scientific deficiencies and is not positioned to meet current or emerging regulatory responsibilities." The authors wrote

that the FDA has become weak and unable to fulfill its mission because of the increasing number of demands and an inability to respond because of a lack of resources. "FDA's inability to keep up with scientific advances means that American lives are at risk," wrote the panelists, adding that the agency can't fulfill its mission "without substantial and sustained additional appropriations." The report was written by Gail Cassell, Ph.D., vice president of scientific affairs at Eli Lilly & Co.; Dr. Allen D. Roses, Jefferson-Pilot Corp. Professor of Neurobiology and Genetics at Duke University; and Dr. Barbara J. McNeil, head of the health care policy department at Harvard Medical School. Members of the Coalition for a Stronger FDA and the FDA Alliance urged Congress to heed the report's warnings. "FDA can't improve its science, prepare for the future, or protect American consumers without significant additional resources," said coalition member Don Kennedy, Ph.D., a former FDA commissioner and editor in chief of the journal *Science*, in a statement.

### Access Reduced by Cost

Forty million Americans can't get access to needed health care, and 20% said the main reason was because they could not afford the services, according to a report issued in December by the Centers for Disease Control and Prevention. *Health, United States, 2007*, is a compilation of pertinent data gathered by the CDC's National Center for Health Statistics. According to the report, in 2005, 1 in 10 people between the ages of 18 and 64 years reported that they had not been able to get prescription drugs in the

past year because of the cost. Another 10% said they had delayed necessary medical care because of cost issues. The report also found that 30% of 18- to 24-year-olds were uninsured, and another 30% of that age group did not have a usual source of medical care. Ten percent of 45- to 64-year-olds did not have a usual source of care. The report highlighted some other age-specific data as well. For instance, about 70% of men and more than 80% of women over age 75 either had hypertension or were taking antihypertensives in 2001-2004, compared with about 35% of adults aged 45-54. And about 20% of 16- to 17-year-olds, and more than 40% of 18- to 25-year-olds reported binge alcohol use in 2005; 20% of the latter age group reported illicit drug use in the previous month.

### DEA Accused of Electronic Stalling

The Drug Enforcement Administration, which investigates crimes involving illicit use of controlled substances, has been criticized for stalling implementation of a national electronic prescribing system for controlled substances. Sen. Sheldon Whitehouse (D-R.I.), speaking at a Senate Judiciary Committee hearing, faulted the DEA's tardiness in developing regulations for such a system and its reluctance to commit to a deadline for completing the regulations. Currently, doctors write prescriptions for controlled substances but can prescribe noncontrolled substances electronically. DEA official Joseph T. Rannazzisi told the committee that the agency is concerned an electronic system would be susceptible to abuse.

—Joyce Frieden

## CLASSIFIEDS

Also Available at [www.clinicalendocrinologynews.com](http://www.clinicalendocrinologynews.com)

### PROFESSIONAL OPPORTUNITIES

#### Southwest Montana Endocrinology Opportunity


**Butte, MT** – Excellent opportunity for (BC/BE) Endocrinologist to join a well-established and busy practice in beautiful, mountainous Southwestern Montana. Competitive salary, benefits and collegial colleagues. St. James Healthcare offers exemplary care in over 30 medical specialties and a Hospitalist program. We have a large primary care referral base to include: adult & child diabetes, female hormone/reproductive cases, thyroid & pituitary problems, some thyroid cancer, and metabolic cases. Involvement in on-going research is available.

St. James Healthcare, a 100 bed acute care state-of-the-art healthcare facility, is located in Butte, Montana, in the heart of the Rocky Mountains. The new Regional Medical Arts Pavilion (RMAP) is connected to the hospital and houses private physician practices, imaging services, an outpatient surgery center, an urgent care facility, laboratory services, and a retail pharmacy.

Butte, a community of 33,000 people (service area of 90,000), is located virtually on the Continental Divide, one of the most beautiful areas of Southwest Montana. Butte has excellent schools along with a local university with 40+ academic programs. Butte has access to world-class trout fishing, golfing, hiking, mountain biking, hunting, skiing, soaking (in commercial hot springs); snowmobiling plus is rich in culture with theatre, live music, festivals, symphonies and museums. Butte is a great place to live, work and play!

For more information, contact:

Kevin (recruiter)  
St. James Healthcare  
406-498-3531  
[kmalee@sjch.org](mailto:kmalee@sjch.org)



Marshfield  
Clinic.

Where the future  
of medicine lives.



Where the future of medicine lives

Marshfield Clinic is an Affirmative Action/Equal Opportunity employer that values diversity. Minorities, females, individuals with disabilities and veterans are encouraged to apply. Sorry, not a health professional shortage area.

Marshfield Clinic is a nationally recognized health care leader and innovator. We provide our physicians with the most advanced medical equipment and health information technology available today. And with a wide range of continuing education opportunities designed to serve the needs of physicians as well as patients.

#### Marshfield Clinic offers:

- A 100% endocrinology practice
- EMR accessed with mobile PC at point of service
- The advantage of practicing where genetic research and educational opportunities are easily accessible
- A community that offers affordable housing, excellent schools, plus proximity to excellent indoor and outdoor recreational activities
- A benefit package including a fully funded retirement plan, matching 401K plan, four weeks paid vacation, two weeks CME with up to \$5,800 allowance, generous relocation, and more

To learn more about an excellent opportunity, please contact: Mary Treichel, Physician Recruiter, Phone: 800-782-8581 extension 19774; Fax: 715-221-9779.

E-mail: [treichel.mary@marshfieldclinic.org](mailto:treichel.mary@marshfieldclinic.org)  
Website: [www.marshfieldclinic.org/recruit](http://www.marshfieldclinic.org/recruit)

### Disclaimer

CLINICAL ENDOCRINOLOGY NEWS assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

### FOR INFORMATION ON CLASSIFIEDS:

Contact Andrea Lamonica  
Elsevier-Clinical Endocrinology News  
1120 Jensen Avenue  
Mamaroneck, NY 10543  
(800) 381-0569 • FAX: (914) 381-0573.  
Email ad to: [a.lamonica@elsevier.com](mailto:a.lamonica@elsevier.com)